Screening Tests for Hypercortisolism in Patients With Adrenal Incidentaloma

Lia Ferreira, Jose Carlos Oliveira, Isabel Palma

Abstract


Background: To compare the diagnostic performance of different first-line screening tests for subclinical hypercortisolism (SH) in patients with adrenal incidentaloma (AI).

Methods: We studied a series of patients with AI, with no clinical evidence of hormonal hypersecretion. For screening for SH, all patients performed 1-mg dexamethasone suppression test (1-mg DST), late night salivary cortisol (LNSC) and 24-h urinary free cortisol (UFC). A control group of patients with confirmed Cushing’s syndrome (CS) was used to calculate the diagnostic performance of the screening tests.

Results: In the 83 patients with AI, morning cortisol after 1-mg DST was ? 1.8 ?g/dL in 69.9%, 1.9 to 5 ?g/dL in 26.5% and > 5 ?g/dL in 3.6%. LNSC was elevated in 20.5% and all patients had normal UFC levels. In the control group, composed of 50 patients with confirmed CS, all patients who underwent 1-mg DST had cortisol levels > 1.8 ?g/dL (1.9 to 5 ?g/dL in 16.2% and > 5 ?g/dL in 83.3%); LNSC was elevated in 93.8% and the UFC was increased in 85.4% of patients tested. Overall, for the screening of SH, the 1-mg DST presented a sensitivity and specificity of 100% and 69.9% with its lowest threshold (? 1.8 ?g/dL) and 83.3% and 96.4% with its highest threshold (< 5 ?g/dL). LNSC showed a sensitivity and specificity of 93.8% and 79.5% and the UFC of 85.4% and 100%, respectively.

Conclusions: The 1-mg DST at its lowest threshold presented the highest sensitivity in identifying SH, but its low specificity encourages us to consider UFC levels, to reduce false-positive test results.




J Endocrinol Metab. 2018;8(4):62-68
doi: https://doi.org/10.14740/jem510w


Keywords


Adrenal incidentaloma; Hypercortisolism, Dexamethasone; Salivary cortisol

Full Text: HTML PDF
 
Home     |     Log In     |      About     |      Search     |      Current     |      Archives     |      Submit      |     Subscribe


 

     

Aims and Scope

Current Issues

Conflict of Interest

About Publisher

Editorial Board

Archives

Copyright

Company Profile

Editorial Office

Misconduct and Retraction

Permissions

Company Registration

Contact Us

Abstracting and Indexing

ICMJE

Ownership

Instructions to Authors

Access

Declaration of Helsinki

Contact Publisher

Submission Checklist

Reprints

Terms of Use

Company Address

Submit a Manuscript

Open Access Policy

Privacy Policy

Browse Journals

Publishing Fee

Publishing Policy

Disclaimer

Recent Highlights

Peer-Review Process

Publishing Quality

Code of Ethics

Advertising Policy

Manuscript Tracking

Advanced Search

For Librarians

Careers

Publishing Process

Publication Frequency

For Reviewers

Propose a New Journal

       
       

Journal of Endocrinology and Metabolism, bimonthly, ISSN 1923-2861 (print), 1923-287X (online), published by Elmer Press Inc.        
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)


This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.jofem.org   editorial contact: editor@jofem.org
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.

DECLARATION: THIS JOURNAL SITE OUTLOOK IS DESIGNED BY THE PUBLISHER AND COPYRIGHT PROTECTED. DO NOT COPY!